After rare disease flop, cash-strapped Quince finds salvation in reverse merger
After launching a hunt for strategic alternatives in January following a phase 3 rare disease flop, Quince Therapeutics has landed on an exit strategy. The Bay...
After launching a hunt for strategic alternatives in January following a phase 3 rare disease flop, Quince Therapeutics has landed on an exit strategy. The Bay Area biotech has announced a merger with a private pulmonary startup called Orphai Therapeutics.